Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2015 Sep;23(9):2833-40.
doi: 10.1007/s00520-015-2809-3. Epub 2015 Jun 17.

Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study

Yolanda Escobar  1 , Gerardo Cajaraville, Juan Antonio Virizuela, Rosa Álvarez, Andrés Muñoz, Olatz Olariaga, María José Tamés, Begoña Muros, María Jose Lecumberri, Jaime Feliu, Purificación Martínez, Juan Carlos Adansa, María José Martínez, Rafael López, Ana Blasco, Pere Gascón, Virginia Calvo, Pablo Luna, Joaquín Montalar, Patricia Del Barrio, María Victoria Tornamira
Affiliations
Observational Study

Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study

Yolanda Escobar et al. Support Care Cancer. 2015 Sep.

Erratum in

Abstract

Purpose: This study aims to determine the incidence of nausea and vomiting (CINV) after moderately emetogenic chemotherapy (MEC), under medical practice conditions and the accuracy with which physicians perceive CINV.

Methods: Chemotherapy-naive patients receiving MEC between April 2012 and May 2013 were included. Patients completed a diary of the intensity of nausea and number of vomiting episodes. Complete response and complete protection were assessed as secondary endpoints.

Results: Of 261 patients included, 240 were evaluated. Median age was 64 years, 44.2 % were female and 11.2 % were aged less than 50 years; 95.3 % of patients received a combination of 5-hydroxytryptamine 3 (5-HT3) antagonist + corticosteroid as antiemetic treatment. Vomiting within 5 days of chemotherapy administration occurred in 20.8 %, nausea in 42 % and significant nausea in 23.8 % of patients. An increase in the percentage of patients with significant nausea (from 9.4 to 21.7 %) and vomiting (from 9.2 to 16.5 %) was observed from the acute to the delayed phase. Complete response was 84.2 % in the acute phase, 77 % in the late phase and 68.9 % in overall period. Complete protection was 79.5 % in the acute phase, 68.8 % in the late phase and 62.4 % throughout the study period. Physicians estimated prophylaxis would be effective for 75 % of patients receiving MEC, compared with 54.1 % obtained from patients' diary.

Conclusion: Despite receiving prophylactic treatment, 31 % of patients did not achieve a complete response and 38 % complete protection. In general, nausea was worse controlled than vomiting. The results also showed the late phase was worse controlled than the acute phase in all variables. Healthcare providers overestimated the effectiveness of antiemetic prophylaxis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Incidence CINV
Fig. 2
Fig. 2
Patients with complete response and complete protection
Fig. 3
Fig. 3
Physicians’ perception vs. study results
See this image and copyright information in PMC

References

    1. Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, Tattersall MH. On the receiving end patient perception of the side effects of cancer chemotherapy. Eur J Cancer Clin Oncol. 1983;19:203–208. doi: 10.1016/0277-5379(83)90418-2. - DOI - PubMed
    1. de Boer-Dennert M, de Wit R, Schmitz PIM, Djontono J, van Beurden V, Stoter G, Verweij J. Patient perception of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer. 1997;76:1055–1061. doi: 10.1038/bjc.1997.507. - DOI - PMC - PubMed
    1. Passik SD, Kirsh KL, Rosenfeld B, McDonald MV, Theobald DE. The changeable nature of patients’ fear regarding chemotherapy: implications for palliative care. J Pain Symptom Manag. 2001;21:113–120. doi: 10.1016/S0885-3924(00)00249-9. - DOI - PubMed
    1. Wagland R, Richardson A, Armes J, Hankins M, Lennan E, Griffiths P (2014) Treatment-related problems experienced by cancer patients undergoing chemotherapy: a scoping review Eur J Cancer Care. doi: 10.1111/ecc.12246 - PubMed
    1. Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29:4189–4198. doi: 10.1200/JCO.2010.34.4614. - DOI - PMC - PubMed

Publication types